SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


November 8, 2006 (Date of earliest event reported)		Commission file number: 000-28131

Pilot Therapeutics Holdings, Inc.
(Exact name of registrant as specified in its charter)


Delaware		56-2280858
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

635 West Fourth Street, Suite 200
Winston-Salem, North Carolina 27101
(Address of principal executive offices)
(Zip code)

(336) 716-4587
(Registrant’s telephone number, including area code)

Item 7

On November 8, 2006, Pilot Therapeutics, Inc. issued a letter to its stockholders with an attached News Release announcing that it had licensed rights to certain of its technology to Efficas Inc. of Boulder, Colorado. A copy of the related letter to stockholders and news release is attached as Exhibit 99.1 to this report, and is incorporated herein by reference.

Item 9

EXHIBITS



99.1		Letter to Stockholders and News Release, dated as of November 8, 2006.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	Pilot Therapeutics Holdings, Inc.

	By:	/s/ Scott Derks

		Scott Derks
		President
Date: November 13, 2006

PILOT THERAPEUTICS HOLDINGS INC 8-K